ChemoCentryx, Inc.
CCXI · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $32 | $65 | $36 | $43 |
| % Growth | -50.3% | 80.5% | -16.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $32 | $65 | $36 | $43 |
| % Margin | 99.1% | 100% | 100% | 100% |
| R&D Expenses | $83 | $78 | $70 | $63 |
| G&A Expenses | $0 | $42 | $24 | $20 |
| SG&A Expenses | $79 | $42 | $24 | $20 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $0 |
| Operating Expenses | $162 | $120 | $94 | $83 |
| Operating Income | -$134 | -$55 | -$58 | -$40 |
| % Margin | -417.2% | -85% | -162.2% | -93.9% |
| Other Income/Exp. Net | -$2 | -$0 | $3 | $2 |
| Pre-Tax Income | -$132 | -$55 | -$55 | -$38 |
| Tax Expense | -$3 | $0 | $0 | $0 |
| Net Income | -$129 | -$55 | -$55 | -$38 |
| % Margin | -400.5% | -85.3% | -154.3% | -88.6% |
| EPS | -1.96 | -0.84 | -0.98 | -0.76 |
| % Growth | -133.3% | 14.3% | -28.9% | – |
| EPS Diluted | -1.96 | -0.84 | -0.98 | -0.76 |
| Weighted Avg Shares Out | 66 | 66 | 57 | 50 |
| Weighted Avg Shares Out Dil | 66 | 66 | 57 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $5 | $4 |
| Interest Expense | -$3 | $3 | $2 | $1 |
| Depreciation & Amortization | $3 | $1 | $2 | $1 |
| EBITDA | -$131 | -$52 | -$52 | -$36 |
| % Margin | -407.5% | -80% | -143.8% | -84.5% |